Company Background

Founded in 2019, Iambic Therapeutics operates a drug discovery platform that combines proprietary AI models with automated, high-throughput chemistry and biology. Its platform operates through a closed-loop process in which AI models propose compounds, robotic laboratories synthesize and test hundreds of compounds per program each week, and the resulting data is used to retrain the models.

The company’s lead candidate, IAM1363, is a selective, brain-penetrant HER2 inhibitor currently in a Phase 1/1b clinical trial for patients with HER2-altered solid tumors. A registrational trial could potentially begin as early as 2027.

Iambic also has two preclinical programs targeting KIF18A and CDK2/4, with investigational new drug applications targeted for the fourth quarter.

The company has generated revenue through collaborations with AbbVie, Takeda, Bayer, and other partners. Iambic reported $18 million in revenue for the 12 months ended June 30, 2026.

IPO Details

Iambic Therapeutics plans to raise up to $100 million through its initial public offering.

The company plans to list on the Nasdaq under the symbol IAM. Iambic filed confidentially with the SEC on July 24, 2026.

J.P. Morgan, Jefferies, BofA Securities, and Citi are serving as joint bookrunners on the offering.

No pricing terms, including the proposed share count or price range, were disclosed.

Market Context & Opportunities

Iambic’s platform combines AI-based compound design with automated laboratory systems, allowing the company to continuously incorporate experimental data into its drug-development models.

Its lead program gives the company exposure to HER2-altered solid tumors, while its preclinical programs expand its potential pipeline into additional biological targets.

The company’s collaborations with established pharmaceutical companies including AbbVie, Takeda, and Bayer have also generated revenue and provide an additional commercial component to its otherwise clinical-stage business.

Risks & Challenges

Iambic remains a clinical-stage biotechnology company, with its lead candidate IAM1363 currently in Phase 1/1b development. Its two additional highlighted programs targeting KIF18A and CDK2/4 remain preclinical.

The potential for a registrational trial as early as 2027 is dependent on the progress of IAM1363 through clinical development. As with other early-stage drug developers, future development outcomes and regulatory progress will remain important factors for the company’s pipeline.

The company also has not yet disclosed pricing terms for the proposed $100 million IPO, leaving the eventual valuation and share structure to be determined.

Closing Paragraph

Iambic Therapeutics is preparing for a proposed $100 million Nasdaq IPO as it brings its AI-driven drug discovery platform to the public markets. With IAM1363 advancing through Phase 1/1b trials and two additional programs targeting KIF18A and CDK2/4 in preclinical development, the company is building a pipeline around its combination of AI models and automated laboratory technology. Its collaborations with AbbVie, Takeda, Bayer, and others have generated revenue, while further clinical development will remain central to its progress as a public company.